Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Rutgers University

Neither a doctor nor a teaching hospital

Research payments

$1,526,217

128 payments

Through program year 2025, Rutgers University is reported as receiving $1,526,217 in research payments, across 128 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $96 1
2024 Research $199,337 20
2023 Research $437,090 25
2022 Research $122,157 7
2021 Research $99,355 11
2020 Research $404,196 32
2019 Research $263,986 32

Breakdown

Who paid Research payments · program years 2019–2025
  1. Epizyme, Inc., $263,900 2 payments
  2. Biogen, Inc. $233,476 11 payments
  3. AstraZeneca AB $217,610 2 payments
  4. Vertex Pharmaceuticals Incorporated $177,722 7 payments
  5. GlaxoSmithKline, LLC. $138,289 30 payments
  6. Regeneron Pharmaceuticals, Inc. $125,186 8 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $67,924 12 payments
  8. Teva Pharmaceuticals USA, Inc. $59,332 1 payment
  9. Shire North American Group Inc $53,321 19 payments
  10. Iovance Biotherapeutics, Inc. $50,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. The Characterization of glucocorticoid receptor (GR) agonists and their differential effects in preventing B2-adrenoceptor agonist-induced tolerance and in broncoprotection of human small airways $217,610 2 payments
  2. A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463 $150,800 1 payment
  3. A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma $113,100 1 payment
  4. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $100,034 3 payments
  5. A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin $77,688 4 payments
  6. Study of BIIB092 in Participants With Progressive Supranuclear Palsy $69,178 2 payments
  7. A First-In-Human Study of Repeat Dosing With Regn2810, A Monoclonal, Fully Human Antibody to Programmed Death - 1 PD 1, As Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies $65,317 6 payments
  8. Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 $64,065 1 payment
  9. An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy (Elm-1) $59,869 2 payments
  10. Evaluation of PAR2 and anti-PAR2 on bronchomotor effects and associated airway inflammatory responses $59,332 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record